In today’s session Edwards Lifesciences Corp (EW) registered an unusually high (3,246) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious EW increase. With 3,246 contracts traded and 8524 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: EW161021C00120000 closed last at: $1.35 or 58.8% up. About 963,406 shares traded hands. Edwards Lifesciences Corp (NYSE:EW) has risen 31.91% since March 14, 2016 and is uptrending. It has outperformed by 26.30% the S&P500.
Analysts await Edwards Lifesciences Corp (NYSE:EW) to report earnings on October, 24. They expect $0.67 EPS, up 24.07% or $0.13 from last year’s $0.54 per share. EW’s profit will be $139.41 million for 42.97 P/E if the $0.67 EPS becomes a reality. After $0.76 actual EPS reported by Edwards Lifesciences Corp for the previous quarter, Wall Street now forecasts -11.84% negative EPS growth.
Edwards Lifesciences Corp (NYSE:EW) Ratings Coverage
Out of 25 analysts covering Edwards Lifesciences Corp (NYSE:EW), 18 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 72% are positive. Edwards Lifesciences Corp has been the topic of 49 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by SunTrust on Friday, January 8. As per Monday, April 4, the company rating was maintained by JP Morgan. Canaccord Genuity maintained the shares of EW in a report on Monday, May 23 with “Buy” rating. On Monday, April 4 the stock rating was maintained by BMO Capital Markets with “Outperform”. The rating was upgraded by Suntrust Robinson to “Buy” on Thursday, January 21. The stock of Edwards Lifesciences Corp (NYSE:EW) earned “Sell” rating by Citigroup on Wednesday, April 27. The company was maintained on Monday, April 4 by Leerink Swann. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, February 3. The stock of Edwards Lifesciences Corp (NYSE:EW) has “Buy” rating given on Tuesday, September 22 by UBS. The company was upgraded on Thursday, January 21 by SunTrust.
According to Zacks Investment Research, “Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Company’s products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.”
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The company has a market cap of $23.96 billion. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It has a 47.64 P/E ratio. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.
EW Company Profile
Edwards Lifesciences Corporation, incorporated on September 10, 1999, is focused on technologies that treat structural heart disease and critically ill patients. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Firm conducts activities around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.
More notable recent Edwards Lifesciences Corp (NYSE:EW) news were published by: Marketwatch.com which released: “Edwards Lifesciences Corp stock up 2% after two heart valves approved for more …” on August 18, 2016, also Wsj.com with their article: “Edwards Lifesciences Raises 2016 View as Earnings, Revenue Top Estimates” published on April 26, 2016, Wsj.com published: “Edwards Lifesciences Shares Soar on Heart-Valve Procedure Study Results” on April 04, 2016. More interesting news about Edwards Lifesciences Corp (NYSE:EW) were released by: Nasdaq.com and their article: “Edwards Lifesciences Corp. Announces 31% Increase In Q2 Earnings” published on July 26, 2016 as well as Marketwatch.com‘s news article titled: “Edwards Lifesciences hikes outlook on strong sales” with publication date: July 26, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.